Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
other
Where this comes from
- Record sourced from PubMed, PMID 26880444.
- Also identified by DOI 10.1016/j.kint.2015.12.038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibition of sodium-glucose cotransporter 2 causes both glycosuria and natriuresis, leading to reductions in hyperglycemia, body weight, blood pressure, and proteinuria. The recently published EMPA-REG OUTCOME study demonstrated significant cardiovascular and mortality benefits of sodium-glucose cotransporter 2 inhibition with empagliflozin in patients with type 2 diabetes and established cardiovascular disease, and may suggest a broader role for sodium-glucose cotransporter 2 inhibition in patients with heart failure.
Medical subject headings
- Benzhydryl Compounds
- Diabetes Mellitus, Type 2
- Glucosides
- Heart Failure
- Hypoglycemic Agents
- Natriuresis
- Sodium-Glucose Transporter 2 Inhibitors